Could a prostate cancer treatment help fight lung cancer?
NCT ID NCT06512207
Summary
This study is testing whether combining a hormone therapy drug (leuprorelin) with an immune-boosting drug (sintilimab) can better control advanced lung cancer. Researchers want to see if the hormone therapy rejuvenates the immune system to make the immunotherapy more effective. The trial is enrolling 80 men aged 60+ with stage III or IV lung cancer who haven't had this type of immune treatment before.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.